Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of IMMU-130 (hMN-14-SN38 Antibody Drug Conjugate) in Patients With Colorectal Cancer.

NCT01270698 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT01270698
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01270698 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of IMMU-130 (hMN-14-SN38 Antibody Drug Conjugate) in Patients With Colorectal Cancer.
Lead sponsor
Gilead Sciences
Phase
Phase 1
Overall status
Completed
Start date
May 31, 2011
Completion date
December 31, 2014
Enrollment
26 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal cancer